LGALS2: A Potential Drug Target and Biomarker (G3957)

Target Name: LGALS2

NCBI ID: G3957

LGALS2

LGALS2: A Potential Drug Target and Biomarker

Lectin, a type of carbohydrate-binding protein, plays a crucial role in many physiological processes in the body. Galactoside-binding proteins (GBPs) are a subfamily of lectins that are involved in the uptake and storage of various carbohydrates, including glucose and galactose. Soluble galactoside-binding proteins (SGBPs) are a specific subclass of GBPs that are characterized by their ability to dissolve in a soluble state and their ability to interact with carbohydrates in a cell-surface dependent manner. LGALS2, a member of the SGBP family, has been identified as a potential drug target and biomarker for various diseases, including diabetes, cancer, and neurodegenerative disorders.

Structure and Function

LGALS2 is a 17-kDa protein that is expressed in various tissues and organs, including brain, pancreas, and muscle. It is composed of 115 amino acid residues and has a calculated molecular mass of 19,112. LGALS2 is characterized by its ability to interact with carbohydrates, particularly galactose, and its soluble state.

The N-terminus of LGALS2 contains a catalytic domain, which is responsible for the carbohydrate binding and catalytic activity of the protein. The catalytic domain is composed of a nucleotide-binding oligomerization (NBO) domain and a hydrogen- bonding-active domain (HB domain). The NBO domain is responsible for the binding of carbohydrates, while the HB domain is responsible for the catalytic activity of the protein.

The C-terminus of LGALS2 contains a region that is involved in the interaction with carbohydrates. This region consists of a carbohydrate-binding module (CBM) and a leucine-rich repeat (LRR) domain. The CBM is responsible for the carbohydrate binding and the LRR domain is involved in the regulation of the carbohydrate binding and storage.

Expression and Localization

LGALS2 is expressed in various tissues and organs, including brain, pancreas, and muscle. It is primarily expressed in the brain, where it is involved in the regulation of carbohydrate metabolism, including the uptake and storage of glucose and galactose. LGALS2 is also expressed in the pancreas, where it is involved in the production of insulin, a hormone that regulates carbohydrate metabolism.

Function and Interaction

LGALS2 has been shown to play a crucial role in the regulation of carbohydrate metabolism and the uptake and storage of glucose and galactose. It is involved in the uptake of glucose and galactose by various cell types, including pancreatic beta cells, muscle fibers, and red blood cells. LGALS2 is also shown to be involved in the storage of glucose and galactose in the liver and muscle.

In addition to its role in carbohydrate metabolism, LGALS2 has also been shown to play a role in the regulation of inflammation and cellular signaling. It is involved in the regulation of the production of pro-inflammatory cytokines, such as TNF-alpha, by dendritic cells and macrophages. It is also involved in the regulation of the production of anti-inflammatory cytokines, such as IL-10, by T-cells.

Drug Targeting

LGALS2 has been identified as a potential drug target for various diseases, including diabetes, cancer, and neurodegenerative disorders. Studies have shown that inhibition of LGALS2 can improve insulin sensitivity and decrease inflammation in various tissues, including the brain.

In addition to its potential therapeutic applications, LGALS2 has also been shown to be a valuable biomarker for various diseases, including diabetes. Studies have shown that LGALS2 levels are significantly decreased in individuals with type

Protein Name: Galectin 2

Functions: This protein binds beta-galactoside. Its physiological function is not yet known

The "LGALS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LGALS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets